Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:

NCT ID: NCT00040755 Completed - Bone Metastases Clinical Trials

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Start date: May 2002
Phase: Phase 2
Study type: Interventional

BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Randomized phase II trial to study the effectiveness of BMS-275291 in treating patients who have prostate cancer that has not responded to hormone therapy

NCT ID: NCT00039442 Completed - Clinical trials for Cervical Adenocarcinoma

Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer

Start date: April 29, 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of capecitabine in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00039403 Completed - Clinical trials for Stage IV Pancreatic Cancer

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Start date: April 2002
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of combining UCN-01 with gemcitabine in treating patients who have unresectable or metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may help gemcitabine kill more cancer cells by making tumor cells more sensitive to the drug

NCT ID: NCT00039104 Completed - Clinical trials for Adenocarcinoma of the Prostate

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Start date: April 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Combining zoledronate with BMS-275291 may kill more tumor cells.

NCT ID: NCT00038168 Completed - Prostate Cancer Clinical Trials

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

Start date: June 2000
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I: The goal of this clinical research study is to find the highest dose of estramustine phosphate administered intravenously in combination with a fixed dose of Taxol (paclitaxel) that can be given safely to participants with prostate cancer who have failed to further benefit from hormone treatment. Phase II: The goal of this clinical research study is to find out if the combination of the drugs estramustine phosphate and paclitaxel will shrink or control prostate cancer that has not responded to hormone treatment. A second goal is to find out if the side effects of these drugs can be reversed. The safety of these drugs will also be studied.

NCT ID: NCT00034190 Completed - Clinical trials for Colorectal Adenocarcinoma

Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma

Start date: March 2002
Phase: Phase 2
Study type: Interventional

Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV colorectal adenocarcinoma.

NCT ID: NCT00032110 Completed - Clinical trials for Recurrent Rectal Cancer

Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Start date: January 2002
Phase: Phase 2
Study type: Interventional

Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or metastatic colorectal cancer.

NCT ID: NCT00031694 Completed - Clinical trials for Stage IV Pancreatic Cancer

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Start date: March 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining paclitaxel and bryostatin-1 in treating patients who have locally advanced unresectable or metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bryostatin-1 may help paclitaxel kill more cancer cells by making tumor cells more sensitive to the drug.

NCT ID: NCT00031681 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Start date: December 2001
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving 7-hydroxystaurosporine together with irinotecan hydrochloride may help kill more cancer cells by making tumor cells more sensitive to the drug.

NCT ID: NCT00028834 Completed - Clinical trials for Stage IV Pancreatic Cancer

Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

Start date: February 2002
Phase: Phase 2
Study type: Interventional

This phase II trial is to see if combining gemcitabine with bevacizumab works in treating patients who have advanced pancreatic cancer. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with a monoclonal antibody may kill more tumor cells